<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086359</url>
  </required_header>
  <id_info>
    <org_study_id>P1039</org_study_id>
    <secondary_id>10046</secondary_id>
    <secondary_id>PACTG P1039</secondary_id>
    <nct_id>NCT00086359</nct_id>
  </id_info>
  <brief_title>Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV</brief_title>
  <official_title>A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Pregnant women infected with HIV who take anti-HIV medications during pregnancy lower the&#xD;
      risk of passing HIV to their infants. This study will compare how well two different&#xD;
      combinations of anti-HIV medications control HIV in pregnancy, and whether these combinations&#xD;
      of drugs are effective in preventing HIV from being transmitted from a pregnant woman to her&#xD;
      baby. The two combinations are abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) and&#xD;
      zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LPV/RTV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiretroviral therapy (ART) in pregnancy has dramatically reduced the rates of perinatal HIV&#xD;
      transmission. Many pregnant women infected with HIV may not meet the criteria for treatment&#xD;
      as set forth by the Department of Health and Human Services' guidelines and would not be&#xD;
      started on therapy if they were not pregnant. Pregnant women are prescribed a variety of&#xD;
      treatment regimens; the optimum regimen for pregnant women who plan to discontinue therapy&#xD;
      after delivery is unknown. An optimum regimen would account for the need for maximum viral&#xD;
      suppression, minimal fetal toxicity, and preservation of future therapeutic options for the&#xD;
      mother. This study will compare an all nucleoside reverse transcriptase inhibitor (NRTI)&#xD;
      regimen of ABC/3TC/ZDV with a standard protease inhibitor (PI) regimen of LPV/RTV and&#xD;
      3TC/ZDV. This study was initially designed for women who plan to take antiretrovirals only&#xD;
      while pregnant and do not meet the criteria for treatment initiation if not pregnant.&#xD;
      However, pregnant women who have taken ART for 180 days or less or have taken ZDV monotherapy&#xD;
      for a total of 8 weeks or less prior to entering this study are eligible for Version 2.0 of&#xD;
      this study.&#xD;
&#xD;
      Women in this study will be randomly assigned to one of two groups. Women in Group A will&#xD;
      receive one pill ABC/3TC/ZDV twice a day. Women in Group B will receive one pill 3TC/ZDV and&#xD;
      4 pills LPV/RTV twice a day. Women will take their assigned medications until they go into&#xD;
      labor. Once in labor, women will be given zidovudine through intravenous (IV) infusion; they&#xD;
      will stop taking oral zidovudine but will continue with their other medications. After&#xD;
      delivery, all infants will be given zidovudine for six weeks.&#xD;
&#xD;
      Women will have study visits every 2 weeks for the first 8 weeks of treatment, and then every&#xD;
      4 weeks until Week 28. Depending on where a woman is in her pregnancy when she enrolls in the&#xD;
      study, she will also have study visits at Weeks 20, 28, and 34 of her pregnancy. At each&#xD;
      visit, women will have a medical interview, a physical exam, and an obstetrical exam; blood&#xD;
      and urine collection will occur at these visits. Mothers will undergo a fetal ultrasound at&#xD;
      Week 20. Adherence, health status, and behavior assessments will occur at selected visits&#xD;
      prior to delivery.&#xD;
&#xD;
      After delivery, women will stop taking the study medications but will continue to have study&#xD;
      visits at approximately 6, 12, 24, 36, 48, and 52 weeks after delivery. Medical history and a&#xD;
      physical exam will occur at all visits for mothers postpartum. Blood collection will occur at&#xD;
      every postpartum visit; urine collection will occur 12, 24, and 48 weeks postpartum; health&#xD;
      status and behavior assessments will occur at most visits postpartum. Infants will have study&#xD;
      visits at 2, 16, and 24 weeks after birth. A medical history, physical exam, and laboratory&#xD;
      tests will be conducted at the infant study visits. Women will also be asked to enroll their&#xD;
      infants in PACTG 219C, a long-term study that follows infants who are born to HIV infected&#xD;
      mothers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women in each treatment group with virologic suppression to less than 400 copies/ml at 34th week of pregnancy (or last viral load prior to delivery, if delivery occurs before 34th week of pregnancy) while continuing on assigned therapy</measure>
    <time_frame>at Week 34 of pregnancy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary outcome, evaluating ART naive and ART experienced women</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-related health status of women at delivery, determined by CD4 counts and plasma HIV-1 viral load in the two treatment groups and in ART naive and ART experienced women</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>study treatment adherence and health status by self report</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-related health status of women postpartum, determined by CD4 counts and plasma HIV-1 viral load</measure>
    <time_frame>at Months 3, 6 and 12 postpartum and prior to ART treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of HIV-1 genotypic resistance among women in each treatment group</measure>
    <time_frame>at delivery, Months 3, 6, and 12 postpartum, and in all cases of treatment failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of abnormal glucose tolerance, gestational diabetes, and abnormal lactate levels during pregnancy in each treatment group</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of anemia, hypoglycemia, abnormal liver function studies, prematurity, low birth weight, or perinatal HIV transmission among infants born to women in each treatment group</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive value, sensitivity, and specificity of polymorphisms in HLA-B57, HLA-DR7, and HLA-DQ3 in identifying pregnant women at risk for development of ABC hypersensitivity</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of T cell receptor rearrangement excision DNA circles</measure>
    <time_frame>at study entry, delivery and 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One pill of abacavir/lamivudine/zidovudine twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate, lamivudine, and zidovudine</intervention_name>
    <description>one pill twice daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/zidovudine</intervention_name>
    <description>one pill twice daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>four pills twice daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Note: The pharmacokinetics testing portion of this study has been discontinued in Version&#xD;
        2.0 of this protocol.&#xD;
&#xD;
        Inclusion Criteria for Mothers:&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  Between the 12th and 30th week of pregnancy&#xD;
&#xD;
          -  Intend to continue pregnancy&#xD;
&#xD;
          -  Viral load less than 55,000 copies/ml within 30 days of study entry&#xD;
&#xD;
          -  CD4 count greater than 350 cells/ml within 30 days of study entry&#xD;
&#xD;
          -  Have not previously taken anti-HIV medications (women who have taken 8 weeks or fewer&#xD;
             of zidovudine are still eligible) OR have taken anti-HIV medication but have been off&#xD;
             treatment for more than 180 days&#xD;
&#xD;
          -  Intend to stop taking anti-HIV medications after pregnancy&#xD;
&#xD;
          -  Willing to have her infant tested for HIV&#xD;
&#xD;
          -  Parent or guardian willing to provide informed consent, if applicable&#xD;
&#xD;
          -  Have access to a participating site and are willing to be followed for the duration of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria for Mothers:&#xD;
&#xD;
          -  Chemotherapy for active cancer&#xD;
&#xD;
          -  Active opportunistic infection or severe medical condition within 14 days of study&#xD;
             entry&#xD;
&#xD;
          -  Chronic diarrhea within 1 month of study entry or unresolved acute diarrhea within 7&#xD;
             days of study entry&#xD;
&#xD;
          -  Certain abnormal laboratory values&#xD;
&#xD;
          -  Diabetes mellitus when not pregnant. Participants who have gestational diabetes are&#xD;
             not excluded.&#xD;
&#xD;
          -  Current alcohol or other substance abuse that, in the opinion of the investigator, may&#xD;
             interfere with the study&#xD;
&#xD;
          -  Acute hepatitis within 90 days of study entry&#xD;
&#xD;
          -  Major birth defects in infant&#xD;
&#xD;
          -  Severe skin disorder (e.g., eczema or psoriasis) requiring systemic treatment&#xD;
&#xD;
          -  Require certain medications&#xD;
&#xD;
          -  Medical condition that may, in the opinion of the investigator, interfere with the&#xD;
             study&#xD;
&#xD;
          -  Intend to breastfeed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D. Hull, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Reproductive Medicine, Division of Perinatal Medicine, University of California, San Diego School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Mother-Child-Adolescent Program CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami Ped. Perinatal HIV/AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens &amp; Childrens HIV Program</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Med. Ctr. at Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVandPregnancy_FS_en.pdf</url>
    <description>Click here for more information about HIV and pregnancy</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPositiveWomenandTheirBabies_FS_en.pdf</url>
    <description>Click here for more information on after birth care for HIV positive women and their babies</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/DrugRegimensPregnantWomen_FS_en.pdf</url>
    <description>Click here for more information on medication regimens for HIV positive pregnant women</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/SafetyandToxicityofAnti-HIVMedsDuringPregnancy_FS_en.pdf</url>
    <description>Click here for more information on medication safety during pregnancy</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1521</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/ElVIHYElEmbarazo_FS_sp.pdf</url>
    <description>Haga clic aquí para más información acerca del VIH y el embarazo</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/LasMujeresVIHPositivasYSusBebesDespuesDelPSarto_FS_sp.pdf</url>
    <description>Haga clic aquí para más información acerca del cuidado de las mujeres VIH positivas y sus bebés después del parto</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/TratamientosParaLasMujeresEmbarazadasInfectadasPorElVIH_FS_sp.pdf</url>
    <description>Haga clic aquí para más información acerca de los tratamientos para las mujeres embarazadas infectadas por el VIH</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/InocuidadYToxicidadDeLosMedicamentosContraElVIHDuranteElESmbarazo_FS_sp.pdf</url>
    <description>Haga clic aquí para más información acerca de la inocuidad de los medicamentos contra el VIH durante el embarazo</description>
  </link>
  <reference>
    <citation>Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.</citation>
    <PMID>11981365</PMID>
  </reference>
  <reference>
    <citation>Scarlatti G. Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Rev. 2004 Apr-Jun;6(2):67-78. Review.</citation>
    <PMID>15332429</PMID>
  </reference>
  <reference>
    <citation>Sullivan JL. Prevention of mother-to-child transmission of HIV--what next? J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S67-72. Review.</citation>
    <PMID>14562860</PMID>
  </reference>
  <reference>
    <citation>Thorne C, Newell ML. Mother-to-child transmission of HIV infection and its prevention. Curr HIV Res. 2003 Oct;1(4):447-62. Review.</citation>
    <PMID>15049430</PMID>
  </reference>
  <reference>
    <citation>Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, O'Sullivan MJ, Scott G, Stek AM, Wara D, Bulterys M. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002 Jun 13;346(24):1863-70.</citation>
    <PMID>12063370</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 30, 2004</study_first_submitted>
  <study_first_submitted_qc>June 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2004</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>Perinatal Transmission</keyword>
  <keyword>Mother-to-Child Transmission</keyword>
  <keyword>MTCT</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

